Core Insights - iRhythm Technologies, Inc. announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025, and appointed Karen McGinnis and Kevin O'Boyle to the board of directors [1][2][4] Group 1: Board Member Changes - Mark Rubash served on the board since 2016, contributing extensive experience in finance, accounting, and strategy [2] - Ralph Snyderman, M.D., joined the board in 2017, providing clinical expertise and guidance during early digital technology challenges [2] - The new board members, Karen McGinnis and Kevin O'Boyle, bring significant financial and operational experience from the medical and biotechnology sectors [3][4] Group 2: New Board Members' Background - Karen McGinnis has over 30 years of experience in leading international companies across various industries, including biotechnology and technology, and previously served as Chief Accounting Officer at Illumina, Inc. [5][6] - Kevin O'Boyle has over 20 years of executive leadership experience, notably as CFO at NuVasive, where he significantly increased the company's market capitalization [9][10] Group 3: Company Vision and Strategy - iRhythm Technologies focuses on creating solutions that detect, predict, and prevent disease through wearable biosensors and cloud-based data analytics [12] - The company aims to deliver better data, insights, and health outcomes for patients globally [12]

Core Viewpoint - DXS International plc's digital medicine solution, ExpertCare, has been selected for the Grow Digital Health Midlands Programme, aimed at scaling digital health innovations across the NHS and broader care system [1][2]. Group 1: Programme Details - The Grow Digital Health Midlands Programme is a collaboration between Health Innovation East Midlands and Health Innovation West Midlands, featuring nine high-potential digital health companies, including DXS [2]. - The programme aims to support UK technology innovators in addressing NHS challenges, focusing on enhancing productivity and communication while reducing hospital care demand [3][4]. Group 2: Selection Process - A total of 51 applications were received, with nine companies selected to receive tailored support, including exposure to NHS England's largest region, covering 11 Integrated Care Systems and a population of approximately 11.8 million [3]. - The selection criteria emphasized the relevance of solutions to NHS priorities and technology readiness [4]. Group 3: Government Alignment - The programme aligns with the UK government's 10 Year Health Plan, which aims to transition from an analogue to a digital system, shift care from hospitals to community settings, and focus on health prevention rather than treatment [5]. Group 4: Company Overview - DXS International provides clinical decision support by presenting up-to-date treatment guidelines from trusted NHS sources to healthcare professionals, ultimately improving healthcare outcomes and contributing to NHS efficiency savings [8].

Core Insights - Biotricity Inc. has been recognized as one of The Americas' Fastest-Growing Companies 2025 by the Financial Times, achieving a remarkable growth rate of 256.4% during challenging global conditions [1][2][3] Company Performance - The evaluation by the Financial Times, in collaboration with Statista, focused on independent companies across the Americas based on revenue growth from 2020 to 2023, amidst significant economic challenges such as the COVID-19 pandemic and supply chain disruptions [2] - Biotricity's growth is attributed to the increasing demand for smart remote monitoring solutions, addressing the needs of over 100 million Americans who face barriers to essential healthcare services [3] Innovation and Market Position - Biotricity is at the forefront of transforming healthcare with proprietary technologies that enhance continuous remote monitoring for high-risk cardiac patients, enabling medical providers to deliver faster interventions and improve patient outcomes [3] - The company's mission to revolutionize chronic care management, particularly in the cardiac sector, is gaining momentum, as highlighted by the recognition from the Financial Times [4]